ADC Therapeutics reports $21M Q3 revenue, restructuring extends cash runway to 2029
ADC Therapeutics reported $21 million in third-quarter revenue and announced financial restructuring with an $86.6 million PIPE that extends its cash runway into 2029. The restructuring strengthens the balance sheet while the company advances its ZYNLONTA pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed